Abstract
Objectives
Drug safety and postmarketing surveillance have become important public health issues in China. This study reviews the relatively new drug safety surveillance system in China and compares it with the systems in the United States and Europe.
Methods
An extensive literature review was conducted in the following four areas: 1) the organizational structure of the State Food and Drug Administration (SFDA) in China; 2) the development of an adverse drug reaction (ADR) monitoring system in China; 3) regulatory issues related to drug safety in China; and 4) similarities and differences between drug safety surveillance in China and surveillance in the United States and Europe.
Results
The SFDA oversees an extensive network of drug safety “watchdogs,” including the China National Center for ADR Monitoring and 32 regional centers throughout China. China's system has faced a number of recent challenges. It has had to respond quickly to the withdrawal of various high-profile drugs like Vioxx (rofecoxib) and Baycol (cerivastatin) from other markets. Together with China's Ministry of Health, the SFDA has faced several unique drug safety events. Three of those events, involving the injectable form of the heartleaf houttuyinia herb (Yu Xing Cao), Armillarisni A injections, and clindamycin glucose infusions (Xinfu), are discussed. The rapid development of drug safety surveillance in China is manifested in extensive organizational structure, development of large databases, and laws and regulations supporting drug safety. The two major laws are the China Drug Administration Law issued in February 2001 and the Regulation for the Administration of ADR Reporting and Monitoring issued in March 2004. The study also discusses and compares recent developments in drug safety surveillance in the United States and the European Union. These developments will most likely have implications for the Chinese system in the near future.
Conclusions
While postmarketing surveillance guidelines are not yet available in China, we fully expect their eventual issuance after adaptation to the particular culture and clinical practices in China.
Keywords: adverse drug reaction, China, drug safety, surveillance
References
- 1.Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41:192–199. doi: 10.1016/s1086-5802(16)31229-3. [DOI] [PubMed] [Google Scholar]
- 2.Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–1205. doi: 10.1001/jama.279.15.1200. [DOI] [PubMed] [Google Scholar]
- 3.Graham DJ, Campen D, Hui R. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475–481. doi: 10.1016/S0140-6736(05)17864-7. [DOI] [PubMed] [Google Scholar]
- 4.Center for Drug Re-evaluation State food and drug administration of China. ADR reporting and monitoring in China. Available from: http://www.who-umc.org [Accessed October 31, 2006].
- 5.Zhou Y, Miller V, Hogan M, Callahan L. An overview of adverse drug reaction monitoring in China. Int J Pharm Med. 2006;20:79–85. [Google Scholar]
- 6.Center for Drug Re-evaluation SFDA. Available from: http://www.cdr.gov.cn/index.jsp [Accessed October 31, 2006].
- 7.Hou YL. ADR reports in China reached anew peak in 2005. China Pharm News. 2006 Section A1. [Google Scholar]
- 8.Clinical Safety Data Management . Definitions and Standards for Expedited Reporting. European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; London: 1995. Available from: http://www.emea.eu.int/pdfs/human/ich [Accessed October 31, 2006]. [Google Scholar]
- 9.Chinese Medical Institute & Register Code of Conduct and Good Practice. Available from: http://www.cmir.org.uk [Accessed April 12, 2007].
- 10.State Food and Drug Administration of China (SFDA) Drug administration law of the People's Republic of China. Available from: http://www.sfda.gov.cn/cmsweb/webportal [Accessed October 31, 2006].
- 11.China Ministry of Health & SFDA Regulation for the administration of adverse drug reaction report and monitoring. Available from: http://www.cdr.gov.cn/doc/content [Accessed October 31, 2006].
- 12.State Food and Drug Administration of China Laws and regulations. Available from: http://www.sfda.gov.cn/cmsweb/webportal [Accessed October 31, 2006].
- 13.Cheng RL. Needs for post-marketing evaluations in China. Chin J Pharmacovigilance. 2005;2:220–225. [Google Scholar]
- 14.The network of ADRs monitoring in China. Available from: http://www.adr.gov.cn [Accessed October 31, 2006].
- 15.Met Q, Zeng C. On the event of ‘Exigent Withdrawal of Houttuynia Cordata Injection’. China Pharm. 2006;17:1124–1126. [Google Scholar]
- 16.Center of Drug Reevaluation, SFDA Questions and answers about the temporally withdrawal of houttuynia herb injections from the market. Available from: http://www.cdr.gov.cn/docbase/infodata [Accessed October 31, 2006].
- 17.Wang Y, Tang Z. The analysis of ADRs related to houttuynia herb injections. Chin J New Drugs. 2006;15:739–741. [Google Scholar]
- 18.Center of Drug Reevaluation, SFDA Warning about the ADRs related to houttuynia herb injections. Available from: http://www.cdr.gov.cn/doc/ [Accessed October 31, 2006].
- 19.Center of Drug Reevaluation, SFDA The new developments and progressions of ADR monitoring and regulations in China. Available from: http://www.cdr.gov.cn/ [Accessed October 31, 2006].
- 20.State Food and Drug Administration of China The notice about the temporally withdrawal of houttuynia herb injections from the market. Available from: http://www.sfda.gov.cn/eng/ [Accessed October 31, 2006].
- 21.State Food and Drug Administration of China The notice about the regulations of the seven houttuynia herb injections. Available from: http://www.sfda.gov.cn/eng/ [Accessed October 31, 2006].
- 22.State Food and Drug Administration of China The National report about Xinfu ADRs by August 13, 2006. Available from: Http://News.Sohu.Com/S2006/Xinfu/ [Accessed September 22, 2006].
- 23.China Daily Drug that has sickened dozens banned. 2006. Available from: http://www.chinadaily.com.cn/china/2006-08/04 [Accessed September 22, 2006].
- 24.State Food and Drug Administration of China The investigation results of clindamycin phosphate glucose injection produced by the Anhui Huayuan Pharmacy Co. Available from: http://www.sfda.gov.cn/cmsweb/webportal [Accessed October 31, 2006].
- 25.Zamiska N, Hanting T. China government cited in medicine probe. Wall Street Journal. 2007. Available from: http://online.wsj.com [Accessed April 8, 2007].
- 26.United States FDA FDA issues final risk minimization guidance. Available from: http://www.fda.gov/bbs/topics/news/2005 [Accessed October 31, 2006].
- 27.FDA Premarketing risk assessment guidance. Available from: http://www.fda.gov/cder/guidance [Accessed October 31, 2006].
- 28.FDA Development and use of risk minimization action plans. Available from: http://www.fda.gov/cder/guidance [Accessed October 31, 2006].
- 29.FDA Good pharmacovigilance practices and pharmacoepidemiologic assessment. Available from: http://www.fda.gov/cder/guidance [Accessed October 31, 2006].
- 30.European Medicine Agency (EMeA) Guideline on risk management systems for medicinal products for human use. Available from: http://www.emea.eu.int/pdfs/human [Accessed October 31, 2006].